Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOSOL 5% vs COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Total parenteral nutrition in patients with inadequate oral or enteral intake,Correction of negative nitrogen balance in malnourished patients
Adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Digoxin toxicity (off-label),Hyperthyroidism (off-label),Pseudomembranous colitis (off-label)
Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
5-10 g orally once or twice daily, maximum 30 g/day.
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Excretion of nitrogenous waste as urea occurs renally.
Not absorbed systemically; not metabolized; excreted unchanged in feces.
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Amino acids are not protein-bound; they exist free in plasma. Minimal reversible binding to albumin occurs for some amino acids, but overall binding is <10%.
Not significantly absorbed; binding not applicable
The volume of distribution for amino acids is approximately 0.3-0.4 L/kg, reflecting distribution primarily in extracellular fluid and to a lesser extent intracellularly.
Not applicable (non-absorbed; confined to gastrointestinal lumen)
Intravenous: 100% bioavailability. Not administered via other routes; oral or enteral administration is not applicable due to hepatic first-pass metabolism and different pharmacokinetics.
Oral: <0.05% (negligible systemic absorption)
In GFR < 50 m L/min: reduce infusion rate by 50% and monitor nitrogen balance. In ESRD on dialysis: use only if essential; typical dose 0.5-0.6 g/kg/day of amino acids with careful monitoring.
No specific dosage adjustment required for renal impairment; use with caution in patients with renal dysfunction due to potential for hyperchloremic metabolic acidosis.
Contraindicated in severe hepatic failure (Child-Pugh C) due to risk of hepatic encephalopathy. In Child-Pugh A or B, use with caution and reduce dose by 30-50%; monitor ammonia levels.
No specific dosage adjustment required for hepatic impairment; use with caution in patients with pre-existing gastrointestinal disorders.
Infants and children: 1-2 g/kg/day of amino acids via total parenteral nutrition (TPN) as a 5% solution. Adjust based on age, weight, and clinical condition. Maximum infusion rate 0.1 g/kg/hour.
Safety and efficacy not established; limited data suggest 5-10 g daily in divided doses for children aged 12-18 years.
Start at lower end of dosing; monitor renal function (creatinine clearance) and avoid fluid overload. Typical initial dose: 0.8-1 g/kg/day of amino acids, adjusted to tolerance and clinical response.
No specific dosage adjustment; monitor for constipation and gastrointestinal adverse effects; initiate at low end of dosing range.
None.
No FDA black box warning.
Use with caution in patients with renal impairment (risk of azotemia and electrolyte imbalances),Monitor serum electrolytes, blood glucose, and fluid balance regularly,Risk of hyperglycemia in diabetic patients; adjust insulin accordingly,Possible hyperammonemia, especially in patients with hepatic insufficiency,Contains aluminum; may accumulate in renal impairment, leading to osteomalacia or neurotoxicity
May cause fecal impaction, especially in patients with hemorrhoids or constipation.,May interfere with absorption of fat-soluble vitamins (A, D, E, K).,May reduce absorption of other drugs; take other medications at least 1 hour before or 4-6 hours after colestipol.,Use with caution in patients with bleeding tendencies or with impaired hepatic function.,Hypertriglyceridemia may occur.
Severe hepatic failure with encephalopathy,Severe uremia without dialysis,Inborn errors of amino acid metabolism,Hypersensitivity to any component
Complete biliary obstruction,Hypersensitivity to colestipol or any component of the formulation
No direct food interactions as Aminos 5% is administered intravenously. However, oral dietary intake must be coordinated with total parenteral nutrition to avoid excessive protein or electrolyte intake.
Colestipol may bind to fat-soluble vitamins (A, D, E, K) and decrease their absorption. Take vitamin supplements at least 1 hour before or 4 hours after colestipol. High-fat meals may reduce binding efficacy; take with meals containing moderate fat.
Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with Aminosol 5%. Therefore, the teratogenic risk is not well defined. However, as a component of parenteral nutrition, it is considered essential for maternal and fetal health when indicated. Use only if clearly needed, weighing potential benefits against unknown risks. No specific trimester-associated risks have been reported.
FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefore, fetal risk is considered minimal. Trimester-specific risks: First trimester: No known risk due to lack of absorption. Second and third trimesters: Potential for decreased absorption of fat-soluble vitamins and folate, which may affect fetal development. Vitamin K deficiency may increase neonatal bleeding risk.
Aminosolic 5% is a mixture of amino acids naturally present in human milk. Administration to lactating women may result in excretion of amino acids into breast milk, but the amounts are unlikely to be clinically significant. The M/P ratio is not known. Caution is advised, but use is generally considered compatible with breastfeeding when clinically indicated.
Colestipol is not absorbed systemically, thus is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for potential gastrointestinal effects secondary to maternal use.
Standard adult dosing (5% solution, 500-1000 m L/day) may be used; however, increased fluid volume and metabolic demands in pregnancy may require dose adjustments. Monitor for fluid overload and adjust infusion rate accordingly. No specific dose adjustment recommendations are established; use caution and individualize based on clinical status.
No dose adjustment required due to lack of systemic absorption. However, ensure adequate nutritional status: monitor fat-soluble vitamin supplementation (A, D, E, K) and folate; increase interval between colestipol and prenatal vitamins/food to 1 hour before or 4 hours after.
Aminos 5% is a crystalline amino acid solution used for parenteral nutrition. In renal failure, adjust dose to limit nitrogen load; monitor BUN. In hepatic encephalopathy, consider branched-chain amino acid formulations. Do not administer concurrently with blood products through same IV line due to risk of agglutination. Infuse via central line if peripheral veins insufficient; peripheral administration requires adequate lipid-based calorie co-administration to prevent phlebitis.
Colestipol is a bile acid sequestrant; administer with meals to bind bile acids. Monitor for constipation and increase fluid/fiber intake. Reduce doses of other medications by at least 1 hour before or 4 hours after colestipol. May increase triglyceride levels; monitor lipids. Use with caution in patients with renal impairment.
This solution provides essential building blocks (amino acids) for protein synthesis when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or drainage.,Tell your doctor if you experience nausea, vomiting, or headache; dose adjustment may be needed.,Do not abruptly stop this infusion; it is part of your total nutrition plan.,Regular blood tests will be required to monitor kidney and liver function.
Take exactly as prescribed, usually once or twice daily with food and a full glass of water.,Do not take other medications within 1 hour before or 4 hours after colestipol.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Inform your doctor if you have a history of hemorrhoids or digestive problems.,Keep out of reach of children; store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOSOL 5% vs COLESTID, answered by our medical review team.
AMINOSOL 5% is a Parenteral Nutrition Solution that works by Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.. COLESTID is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOSOL 5% and COLESTID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOSOL 5% is: Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.. The standard adult dose of COLESTID is: 5-10 g orally once or twice daily, maximum 30 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOSOL 5% and COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOSOL 5% is classified as Category C. Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies hav. COLESTID is classified as Category C. FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.